Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04216394 · ClinicalTrials.gov registry record

Anticoagulation in Emergency General Surgery

A clinical trial of Emergency General Surgery, sponsored by Methodist Health System.

Completed
Registry status
4
Enrollment target
1
Study location

NCT04216394 is a study of Emergency General Surgery that has completed, run by Methodist Health System. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04216394, a study of Emergency General Surgery, has completed, sponsored by Methodist Health System.

COMPLETED
Registry status
4 participants
Enrollment target
1
Study location

Study Summary

While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the EGS population taking DOACs. We hypothesize that patients taking a DOAC will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in EGS patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.

Conditions Studied

Interventions

  • PROCEDURE Emergency general surgery

Study Locations (1)

Texas

  • Methodist Dallas Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2019-10-31
Est. Completion 2020-11-13

Sponsor

Methodist Health System

125 total trials

What the Registry Record Tells You About NCT04216394

The ClinicalTrials.gov registry entry for NCT04216394 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Emergency General Surgery appearing as the primary indexed condition, and to 1 intervention - of which Emergency general surgery is the first listed.

NCT04216394 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04216394 about?

NCT04216394 is a clinical study titled "Anticoagulation in Emergency General Surgery". While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outc...

What is the current status of trial NCT04216394?

This trial is currently completed. The enrollment target is 4 participants. The study started on 2019-10-31. Estimated completion is 2020-11-13.

What conditions does trial NCT04216394 study?

This clinical trial studies the following conditions: Emergency General Surgery.

What interventions are being tested in trial NCT04216394?

The interventions under investigation include: Emergency general surgery (PROCEDURE).

Who is sponsoring clinical trial NCT04216394?

This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04216394 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.